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Tissue-type plasminogen activator (tPA) and its substrate plasminogen (Plg) are key components in the fibrinolytic system. We have recently
demonstrated, that truncated human recombinant soluble melanotransferrin (sMTf) could stimulate the activation of Plg by urokinase plasminogen
activator and inhibit angiogenesis. Since various angiogenesis inhibitors were shown to stimulate tPA-mediated plasminogen activation, we
examined the effects of sMTf on tPA-dependent fibrinolysis. This study demonstrated that sMTf enhanced tPA-activation of Plg by 6-fold. sMTf
also increased the release of [125I]-fibrin fragments by tPA-activated plasmin. Moreover, we observed that the interaction of sMTf with Plg
provoked a change in the fibrin clot structure by cleaving the fibrin α and β chains. Overall, the present study shows that sMTf modulates tPA-
dependent fibrinolysis by modifying the clot structure. These results also suggest that sMTf properties could involve enhanced dissolution of the
provisional extracellular fibrin matrix.
© 2006 Elsevier B.V. All rights reserved.Keywords: Fibrin matrix; Melanotransferrin; Plasminogen1. Introduction
Plasmin is a serine protease that dissolves fibrin clots.
Tissue-type plasminogen activator (tPA) plays a key role in
fibrinolysis because tPA converts inactive plasminogen (Plg)
into enzymatically active plasmin [1]. Melanotransferrin (MTf)
is a 97 kDa glycoprotein that shares substantial sequence
similarity with human serum transferrin, human lactoferrin, and
chicken transferrin [2]. MTf was first identified, in the early
1980s, on the surface of melanoma cells and this glycoprotein is
used as a marker for melanoma cells [3]. More recently, it was
reported that MTf mRNA is present in many normal human
tissues [4]. MTf exists as both membrane-bound and soluble
forms, depending on whether or not this glycoprotein possesses
a glycosylphosphatidylinositol (GPI)-anchor that has been
attached to the glycoprotein [5].⁎ Corresponding author. Tel.: +1 514 987 3000x6697; fax: 1 514 987 0246.
E-mail address: oncomol@nobel.si.uqam.ca (R. Béliveau).
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.08.006Because MTf possesses iron-binding properties, it was first
proposed that MTf might be involved in iron transport [5].
However, MTf has been shown to play a minor role in the
uptake of iron [6]. Recent studies have suggested that MTf
could be involved in pathological and physiological processes,
including Alzheimer's disease [7], chondrogenic differentiation
[8] and transcytosis across the blood–brain barrier [9]. We have
previously shown that membrane-bound MTf could bind and
stimulate Plg activation at the cell surface [10]. In addition, we
also reported that truncated human recombinant soluble
melanotransferrin (sMTf) could catalyze the urokinase type
activator uPA-mediated activation of plasmin and affect cell
migration [11]. We also found that sMTf inhibited endothelial
cell movement and tubulogenesis which are important events in
angiogenesis [12].
The formation of a provisional extracellular fibrin matrix
(PEFM) is an important step in cell migration. This occurs after
vascular injury, during inflammation, and in tumors. These
phenomenons induce the expression of tissue factor on the
endothelial cells [13]. Tissue factor, which is not only present on
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onmany tumor cells, triggers the formation of PEFM [14]. Fibrin
and the other components of this extracellularmatrix are involved
in the regulation of cell proliferation and migration through
interactions with adhesion molecules on cell surfaces [15].
Since the conversion of Plg to plasmin by tissue-type
plasminogen activator (tPA) plays a role in fibrinolysis, we
investigated whether sMTf could affect fibrinolysis of PEFM.
The generation of plasmin as well as the release of [125I]-fibrin
fragments by tPA increased in the presence of sMTf. In
addition, sMTf enhanced the tPA-dependent fibrinolysis of both
fibrin clots and platelet-rich plasma (PRP) clots by tPA. Overall,
the different experimental approaches indicated that sMTf
stimulates Plg activation by tPA leading to an increase in the
fibrinolysis of PEFM.2. Materials and methods
2.1. Materials
Truncated human recombinant MTf (sMTf), which is produced by
introducing a stop codon following the glycine residue at position 711 (27 C-
terminal amino acids deletion), and L235 monoclonal antibody (mAb) were
kindly provided by Biomarin Pharmaceutical (Novato, CA). Fibrinogen,
thrombin and tPAwere from Calbiochem (La Jolla, CA). The antibody directed
against MTf (L235) was from American Type Culture Collection (Manassas,
VA). Blood tubes were 3.2% citrate-treated Vacutainers® from Becton
Dickinson (Franklin Lakes, NJ). Human factor XIII Fibrogammin® P (FXIII)
was from Aventis (Marburg, Germany). Plg was from Technoclone (Vienna,
Austria). Other biochemical reagents were from Sigma (Oakville, ON).
2.2. Plasmin activity assay
Human glu-Plg (50 nM) (Technoclone, Vienna, Austria) activation by
human tPA (50 pM) with or without sMTf (500 nM) (Calbiochem, La Jolla, CA)
was measured using a colorimetric assay as previously described [16]. Briefly,
the reaction was performed in a final volume of 200 μl in a suitable medium
(buffer A, consisting of 50 mM Tris/HCl pH 7.4, 150 mM NaCl, and 50 mM
CaCl2). The reaction was started by the addition of tPA. The plasmin produced
cleaved the plasmin substrate (Val-Leu-Lys-p-nitroanilide) (Sigma ,Oakville,
ON). Absorbance was monitored at 405 nm using a Microplate Thermomax
Autoreader (Molecular Devices, Sunnyvale, CA). The L235 mAb (2 μM)
(American Type Culture Collection, Manassas, VA) was used to inhibit sMTf
activity. Concentration variation of sMTf (0–10 μM) determined the apparent
Km to enhance tPa activation of Plg. Km was evaluated using the Prism software
(GraphPad Software Inc, San Diego, CA).
2.3. BIAcore analysis
Glu-Plg (3 μg) was covalently coupled to a sensor chip (CM5) via primary
amine groups using the coupling reagents (N-hydroxysuccinimide (NHS)/
N-ethyl-N′-(dimethylaminopropyl) carbodiimide (EDC)) as previously
described [17]. sMTf was produced following an established protocol [18].
Proteins were injected onto the biological sensor chip surface. The surface
plasmon resonance (SPR) generated by the protein–protein interaction was
monitored in real-time and analyzed with BIAevaluation software (BIAcore,
Piscataway, NJ) to determine the kinetic parameters of interaction.
2.4. Platelet-rich plasma (PRP) preparation
Human blood samples were collected by a two syringe technique, during
which the first ml was discarded, of blood into 3.2% citrate-treated Vacutainers®
(Becton Dickinson, Franklin Lakes, NJ) and centrifuged at 300×g for 5 min atroom temperature. Participating subjects had given informed consent in
accordance with the Declaration of Helsinki.
2.5. Fibrin plate assay
To examine the effects of sMTf on fibrinolysis, we used a [125I]-fibrin plate
assay as previously described [19]. Briefly, in a 24-well microplate, 20 μl of
human, labeled [125I]-fibrinogen (Amersham Biosciences, Bucks, UK) (6 nCi/
assay) at 3 mg/ml were mixed with Plg (2 μM) and introduced into the wells.
Clotting was achieved by the addition of human thrombin (Sigma, Oakville,
ON) (0.4 U/ml) with or without human factor XIII Fibrogammin® P (FXIII)
(Aventis, Marburg, Germany) for 60 min at 37 °C. Clots were carefully washed
three times with the buffer A. Next, the buffer with tPA were carefully layered
onto the surface of the clot and treated with sMTf (500 μM). The release of
[125I]-fibrin fragments into the supernatant (100 μl) during a 15 min incubation
at 37 °C was measured by a LKB Wallac 1282 Compugamma counter (LKB
Instruments, Inc, Gaithersberg, MD).
2.6. PRP fibrinolysis assay
To examine the influence of sMTf on fibrinolysis ex vivo, we used a [125I]-
fibrinogen labeled PRP clot assay. Labeled [125I]-fibrinogen (6 nCi/assay) was
mixed with 20 μl of PRP. Clotting was achieved by the addition of CaCl2
(20 mM final) for 60 min at 37 °C. Next, 100 μl of buffer A containing tPA and
various concentrations of sMTf was layered onto the surface of the clot. The
release of [125I]-fibrin fragments into the supernatant during a 15 min incubation
at 37 °C was measured.
2.7. Radial clot lysis assay
To visualize the enhanced fibrinolysis due to sMTf , radial clot lysis was
performed as previously described by Mosesson [16], with minor modifications.
Briefly, fibrin clots were obtained by incubating fibrinogen (8.2 μM), Glu-Plg
(2 μM) and 0.4 U/ml thrombin in buffer A at 37 °C for 60 min in a 6-well plate.
Clot lysis was initiated by adding 2 μl of tPA (1 nM) with or without sMTf
(100 nM). Clots were incubated for 30 min at 37 °C and dyed with Chinese ink.
Photomicrographs at 40× magnification were taken using a Nikon Coolpix 5000
digital camera attached to a Nikon TMS-F microscope (Nikon Canada,
Mississauga, ON).
2.8. Cleavage of fibrin clot by sMTf
To visualize the influence of hr-sMTf on the fibrin clot, we incubated
fibrinogen, Plg and thrombin at 37 °C for one h. After the clot had polymerized,
the clot was treated with hr-sMTf for 8 h at 37 °C. The clot was then dissolved
under reducing conditions [20]. Electrophoresis was carried out on a 9%
acrylamide gel at 100 V for 2 h. The gel was dyed afterwards with Coomassie
blue. Protein sequencing was performed by NRC Protein and Peptide
Sequencing (Montreal, QC).
2.9. Thromboelastography analysis
Thromboelastography analysis was performed with PRP or with an artificial
clot model using a computerized dual-channel thromboelastograph (TEG)
analyzer (model 5000; Haemoscope Corp., Niles, IL). For the artificial clot
model, fibrinogen (8.2 μM) (Sigma, Oakville, ON), Glu-Plg (3.3 μM) and tPA
(1 nM) were diluted in buffer A and transferred into the analyzer cups. Artificial
clots were polymerized with thrombin (Sigma, Oakville, ON) (0.4 U/ml). For
the PRP clots, 350 μl of PRP were transferred into the analyzer cups with tPA
(1 nM). CaCl2 (0.2 M) was added to initiate the coagulation of PRP.
Thromboelastography analyses for both artificial clot models and PRP clots
were performed in both the presence and absence of 1 μM sMTf at 37 °C.
2.10. Data analysis
Statistical analyses were performed using Student's t-test via GraphPad
Prism software (San Diego, CA). Significant difference was assumed for P
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standard deviation, measured in triplicate.
3. Results
3.1. Plasmin activity assay
In order to characterize the effect of sMTf on tPA activation
of Plg, the plasmin activity assay was evaluated by the
hydrolysis of VLK p-nitroanilide, a colorimetric substrate of
plasmin (Fig. 1). After 3 h of incubation in the presence of
Plg, sMTf increased the tPA-mediated generation of plasmin by
6-fold (●), compared to tPA alone (○). sMTf with Plg had no
proteolytic or plasmin-like activity itself (■) (Fig. 1a). The
specificity of the effect of sMTf was then determined by
measuring the induction of tPA-dependent Plg activation by
sMTf in the presence of either mAb L235 (○), an antibody
directed against sMTf, or a non-specific IgG used as a control
(●). The L235 mAb (2 μM) inhibited the effect of sMTf on tPA-
induced plasmin generation by 80% (Fig. 1b). To determine the
optimal concentration of sMTf needed to enhance the activation
of Plg by tPA, the half-maximal concentration was determined.
sMTf stimulated the initial rate of tPA-dependent conversion of
Plg into plasmin in a dose-dependent manner with a half-
maximal stimulation occurring at 53±22 nM (Fig. 1c). The
effect of sMTf on plasmin formation by tPA was further
evaluated in the presence of various concentrations of Plg.Fig. 1. Effects of sMTf on tPA-dependent plasmin activity. (a) The plasmin activity in
The reaction was performed as described in Materials and methods. The plasminolyti
based upon 3 independent experiments. *P< 0.05 vs. tPA. (b) The plasmin activity in
(○) or a non-specific mouse IgG (●). (c) Plasmin activity induced by tPA was
concentrations. (d) Initial rates of VLK-hydrolysis during Plg activation by tPAwere m
of Plg. Data shown are means±SD of 3 different experiments.Initial rates of plasmin activity indicated that sMTf decreased
the apparent Km of tPA for Plg from 280 nM (○) to 52 nM (●)
(Fig. 1d).
3.2. BIAcore analysis
The ability of sMTf to interact with Plg was monitored in
real-time using a BIAcore apparatus. Standard NHS/EDC
coupling procedures [17] permitted immobilization of Plg on
the BIAcore sensor chip surface. Injections of sMTf over
immobilized Plg generated SPR, which increased in an sMTf
concentration-dependent fashion (Fig. 2). Using this approach,
the apparent equilibrium dissociation constant KD, calculated
with the Biaevaluation software, was 260 nM. The best fit used
was the two state reaction (conformation change).
3.3. Fibrin plate assay
We next measured the release of [125I]-fibrin fragments from
labeled clots after adding with Plg at a physiological
concentration to determine the effect of sMTf on fibrinolysis
(Fig. 3). sMTf increased the release of [125I]-fibrin fragments
by 2.5 fold following Plg activation by tPA (Fig. 3a). The
release of [125I]-fibrin fragments was next measured from clots
produced in the presence of factor XIII (Fig. 3b) and showed
that a higher concentration of tPA was needed to release the
same amount of [125I]-fibrin fragments as was released in theduced by tPAwas measured without (○) or with sMTf (●) in the presence of Plg.
c activity in the presence of sMTf (■) alone was also measured. Data shown are
duced by tPAwas measured in the presence of sMTf with either the mAb L235
determined by measuring VLK-hydrolysis in the presence of various sMTf
easured without (○) or with (●) sMTf in the presence of various concentrations
Fig. 4. Modulation of tPA-dependent fibrinolysis of PRP clot by sMTf. Release
of [125I]-fibrin fragments was measured in PRP containing tPA with varying
concentrations of sMTf. The data shown are from 3 independent experiments.
Values are means±SD. *P<0.05 vs. tPA.
Fig. 2. Biospecific interaction analysis in real-time between sMTf and Plg. sMTf
diluted in Buffer A was injected onto immobilized Plg on a sensor chip as in
Materials and methods. The SPR response for these proteins was plotted in
response units (RU) as a function of time.
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fragment release from PRP clots in the presence of tPA (Fig. 4).
In this assay system, the apparent concentration of sMTf
needed to support a 50% maximal [125I]-fibrin fragment
released by tPA is 96 nM.
3.4. Radial clot lysis assay
To further demonstrate the effect of sMTf on tPA-induced
clot lysis, a radial clot lysis assay was used. (Fig. 5). The
addition of sMTf to tPA enhanced fibrinolysis, leading to
increased dissolution of the fibrin clot (Fig. 5a). In the absence
of tPA, the addition of sMTf to Plg modified the fibrin clot
structure, whereas sMTf in the absence of Plg did not seem to
affect it. (Fig. 5b).Fig. 3. Impact of sMTf on tPA-dependent fibrinolysis. (a) Release of [125I]-fibrin
fragments was measured in the presence of sMTf, tPA (50 pM) or both sMTf and
tPA, and was quantified using a gamma scintillation counter. Relative release
was established as 1-fold for tPA. Data shown (means and SD) are from 8
experiments. **P<0.002 vs. baseline. ***P<0.001 vs. tPA (b) Fibrin release
was compared between clots which had been crosslinked with FXIII (1U/ml)
using two different conditions, tPA (1 nM) and tPA + sMTf (500 nM).
***P<0.001 vs. tPA. Data shown (means and SD) are from 8 experiments.3.5. Evaluation of fibrin fragmentation
The fibrin fragmentation pattern was next analyzed in the
absence of tPA to further investigate the effects of sMTf on
the fibrin clot structure. The fragmentation pattern was
obtained by measuring the migration of treated fibrin clots
on acrylamide gels by electrophoresis under reducing condi-
tions (Fig. 6). Electrophoresis performed in the presence of the
reducing agent β-mercaptoethanol allowed visualization of the
2 chains of fibrin (α, β). The addition of either sMTf or Plg
did not affect the electrophoresis separation profiles. However,Fig. 5. Effect of sMTf on clot fibrinolysis with tPA. (a) Human fibrinogen was
clotted with thrombin in the presence of Plg in a 6 well plate. In each well, a 2 μl
volume of either tPA, tPA + sMTf or sMTf alone was laid down onto the fibrin
clot. Clots were dyed with Chinese ink and digitally measured. Experiments
shown are representative of multiple independent experiments. (b) The fibrin
clot was treated with sMTf in the presence or absence of Plg. Photographs were
taken at 100× magnification.
Fig. 7. Effect of MTf on clot strength and fibrinolysis. Representative tracing
showing effects of MTf (500 nM) on clot strength in relative units (RU) during
the fibrinolysis of clot formation under shear by TEG. (a) Thromboelastogram of
the fibrin clot model. (b) Thromboelastogram of PRP clotted after addition of
CaCl2 (2 mM). The results shown here are representative of 3 different
experiments.
Table 1
Effect of MTf on thromboelastograph parameters
Parameters Conditions
tPA tPA + MTf
(a) Artificial fibrin-clot
(1) MA 498±7 446±17
(2) LY30 % 25.0±8.2 72.5±20.4
(3) CLT min 54.3±10.0 37.8±3.8
(b) Fibrin-clot with PRP
(1) MA 13465±1586 9560±1626
(2) LY30 % 4.3±0.7 11.8±4.0
(3) CLT min 68.3±1.6 49.1±6.3
The three parameters obtained with the thromboelastograph are presented as
follows: 1. MA is the maximum strength of the clot at maximum amplitude of
the TEG trace., 2. The percentage of lysis at 30 min (LY 30). 3. The complete
clot lysis time in minutes (CLT).
Fig. 6. Degradation of human fibrin (Fn). Human fibrinogen (Fg), Plg and
thrombin were incubated at 37 °C for one h. After the clot had polymerized, the
clot was treated with sMTf for 8 h at 37 °C. The clot was then dissolved under
reducing conditions [20]. Electrophoresis was carried out on a 9% acrylamide
gel at 100 V for 2 h. The gel was dyed afterwards with Coomassie blue. Protein
sequencing was performed to determine the site of cleavage.
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altered the separation profile. Both chains (α and β) of fibrin
almost completely disappeared, leaving a fragment of 37 kDa.
Peptide sequencing of the 37 kDa fragment N-terminal region
produced the sequence DVENV, which represents the region
between Asp165 and Val169 of the fibrin β-chain.
3.6. Evaluation of clot viscoelastic properties
Since MTf potentiates Plg activation by tPA, the impact of
MTf on clot formation and lysis was therefore evaluated using
TEG analysis (Fig. 7). An artificial fibrin-clot model formed by
the action of thrombin on fibrinogen was first used (Fig. 7a).
This model allowed examination of the effect of MTf on tPA-
fibrinolysis in the absence of inhibitors. Monitoring of the TEG
parameters indicated that addition of MTf increased the
thrombolytic activity of tPA (Table 1). In particular, when
MTf (500 nM) was added to tPA, clot lysis after 30 min (LY30)
was 5 times higher than that observed in the absence of MTf
while the complete lysis time (CLT) diminished by 30%. The
impact of MTf on fibrin-clot dissolution was further evaluated
using PRP (Fig. 7b). The TEG parameters obtained for these
experiments (Table 1) indicated that the addition of MTf to tPA
caused a 30% decrease in the maximum clot strength (MA),
doubled the LY30 rate and reduced the CLT by 20%.
4. Discussion
Previous studies showed that various angiogenesis inhibitors
stimulate tPA-mediated plasminogen activation [21–23]. The
plasminogen activation system, which leads to the formation of
the serine protease plasmin and to subsequent fibrinolysis, has
been shown to play an important role in the breakdown of the
PEFM, one of the hallmark of angiogenesis [24]. We report here
that sMTf enhances the formation of plasmin by tPA by
interacting with Plg. In haemostasis, tPA is predominantly
secreted by endothelial cells and cleaves circulating Plg into
plasmin which is the enzyme responsible for proteolytic
degradation of fibrin [19]. The apparent Km for Plg cleavage
by tPA was similar to that measured in a previous study [22].
The action of sMTf on Plg reduced the Km for tPA by 5 fold.Inhibition by the L235 mAb of the ability of sMTf to induce the
activation of Plg by tPA suggests that its interaction with Plg is
specific and might involve the conformational epitope recog-
nized by this mAb [25]. The ability of the anti-MTf antibody to
block this inductive effect confirms that the biologically active
factor was sMTf itself rather than a contaminating factor. The
interaction of sMTf with immobilized Plg confirmed results
from a previous study, where we showed that Plg could interact
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both studies. Several reports have established that protein–
protein interactions can positively modulate the activity of an
enzyme [26]. Thus, sMTf can be viewed as a positive modulator
of tPA-dependent Plg activation and dose response studies have
revealed that sMTf is active in the nM range. sMTf modulates
the tPA-induced release of [125I]-fibrin fragments from artificial
clots and from PRP clots. Although the introduction of factor
XIII augments resistance to tPA-induced fibrinolysis [27], the
addition of sMTf still increased the release of [125I]-fibrin
fragments. The clot assay provides another line of evidence that
the activation of Plg by tPA is increased by sMTf and leads to
enhanced dissolution of the PEFM. Fibrin is not strictly required
for tumor angiogenesis: however, the absence of fibrin in a
knock-out model strongly diminishes the aggressiveness of the
tumor [28].
Previous studies have established a clear link between
modification of the fibrin clot structure, allowing better
penetration of tPA, and acceleration of tPA-dependent clot
dissolution [29]. These observations are supported by the
degradation pattern of fibrin in the presence of Plg and sMTf,
which demonstrated a cleavage of the fibrin β chain and the
degradation of the α chain in the absence of tPA. γ chain under
these conditions forms dimers (≅100 kDa) that migrate in the
same region of sMTf and Plg [30]. The cleavage of the β chain
in the presence of sMTf would thus increase the accessibility of
Plg for tPA. Since a higher rate of clot lysis is observed with the
increased access of Plg [31], increased accessibility of Plg by
sMTf could greatly facilitate the action of tPA. Moreover, the
lysis of composite fibrin fibres initiated by either plasmin or tPA
proceeds preferentially by lateral section of fibers, rather than
by uniform thinning of the whole fibre [32]. This change in
fibrin architecture is also visible by the diminished strength and
accelerated fibrinolysis of the clot. The cleavage of the α and β
chains would fragment the lateral section released and
accelerate the degradation of the fibrin. This phenomenon
could prevent the exposition of binding sites for anchor
receptors of endothelium cells or tumor cells in the PEFM [33].
In conclusion, these first results clearly demonstrated that
sMTf catalyzes the activation of Plg by tPA, leading to
enhanced tPA-mediated fibrinolysis. Thus, sMTf affects the
activation of Plg by both activators: urokinase [10–12] and tPA.
Our data demonstrate that sMTf, in combination with Plg in the
PEFM, modifies the fibrin clot structure. These are the first
results suggesting that administration of sMTf could impair the
PEFM needed both by the endothelium to produce new
capillary networks and by tumor cells to migrate. Further
studies are underway to elucidate whether endogenous MTf
could be related to fibrinolysis-associated events like vascular
disease.
Acknowledgements
We thank Dr. A. Regina, Y. Rolland, and J Michaud-
Levesque for the critical reading of this manuscript. This work
was supported by grants from the Canadian Institutes of Health
Research to R.B.References
[1] D.C. Rijken, D.V. Sakharov, Basic principles in thrombolysis: regulatory
role of plasminogen, Thromb. Res. 1 (2001) S41–S49.
[2] J.P. Brown, R.M. Hewick, I. Hellstrom, K.E. Hellstrom, R.F. Doolittle,
W.J. Dreyer, Human melanoma-associated antigen p97 is structurally
and functionally related to transferrin, Nature 296 (1982) 171–173.
[3] J.P. Brown, R.G. Woodbury, C.E. Hart, I. Hellstrom, K.E. Hellstrom, Proc.
Natl. Acad. Sci. U. S. A. 78 (1981) 539–543.
[4] E.O. Sekyere, L.L. Dunn, D.R. Richardson, Examination of the
distribution of the transferrin homologue, melanotransferrin (tumour
antigen p97), in mouse and human, Biochim. Biophys. Acta 1722 (2005)
131–142.
[5] M.R. Food, S. Rothenberger, R. Gabathuler, I.D. Haidl, G. Reid, W.A.
Jefferies, Transport and expression in human melanomas of a transferrin-
like glycosylphosphatidylinositol-anchored protein, J. Biol. Chem. 269
(1994) 3034–3040.
[6] D.R. Richardson, E.H. Morgan, The transferrin homologue, melanotrans-
ferrin (p97), is rapidly catabolized by the liver of the rat and does not
effectively donate iron to the brain, Biochim. Biophys. Acta 1690 (2004)
124–133.
[7] R.R. Desrosiers, Y. Bertrand, Q.T. Nguyen, M. Demeule, R. Gabathuler,
M.L. Kennard, S. Gauthier, R. Beliveau, Biochem. J. 374 (2003) 463–471.
[8] K. Nakamasu, T. Kawamoto, M. Shen, O. Gotoh, M. Teramoto, M.
Noshiro, Y. Kato, The transferrin homologue, melanotransferrin (p97), is
rapidly catabolized by the liver of the rat and does not effectively donate
iron to the brain, Biochim. Biophys. Acta 1447 (1999) 258–264.
[9] M. Demeule, J. Poirier, J. Jodoin, Y. Bertrand, R.R. Desrosiers, C.
Dagenais, T. Nguyen, J. Lanthier, R. Gabathuler, M. Kennard, W.A.
Jefferies, D. Karkan, S. Tsai, L. Fenart, R. Cecchelli, R. Beliveau,
Expression of melanotransferrin isoforms in human serum: relevance to
Alzheimer's disease, J. Neurochem. 83 (2002) 924–933.
[10] J. Michaud-Levesque, M. Demeule, R. Beliveau, Stimulation of cell
surface plasminogen activation by membrane-bound melanotransferrin: a
key phenomenon for cell invasion, Exp. Cell Res. 308 (2005) 479–490.
[11] M. Demeule, Y. Bertrand, J. Michaud-Levesque, J. Jodoin, Y. Rolland, R.
Gabathuler, R. Beliveau, Regulation of plasminogen activation: a role for
melanotransferrin (p97) in cell migration, Blood 102 (2003) 1723–1731.
[12] J. Michaud-Levesque, Y. Rolland, M. Demeule, Y. Bertr, R. Beliveau,
Inhibition of endothelial cell movement and tubulogenesis by human
recombinant soluble melanotransferrin: involvement of the u-PAR/LRP
plasminolytic system, Biochim. Biophys. Acta 1743 (2005) 243–253.
[13] S. Zucker, H. Mirza, C.E. Conner, A.F. Lorenz, M.H. Drews, W.F. Bahou,
J. Jesty, Vascular endothelial growth factor induces tissue factor and matrix
metalloproteinase production in endothelial cells: conversion of prothrom-
bin to thrombin results in progelatinase A activation and cell proliferation,
Int. J. Cancer 75 (1998) 780–786.
[14] H.F. Dvorak, L.F. Brown, M. Detmar, A.M. Dvorak, Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeabil-
ity, and angiogenesis, Am. J. Pathol. 146 (1995) 1029–1039.
[15] B.P. Eliceiri, D.A. Cheresh, The role of alphav integrins during
angiogenesis: insights into potential mechanisms of action and clinical
development, J. Clin. Invest. 103 (1999) 1227–1230.
[16] M.W. Mosesson, S. Sherry, The preparation and properties of human
fibrinogen of relatively high solubility, Biochemistry 5 (1966) 2829–2835.
[17] D.J. O'Shannessy, M. Brigham-Burke, K. Peck, Immobilization chemis-
tries suitable for use in the BIAcore surface plasmon resonance detector,
Anal. Biochem. 205 (1992) 132–136.
[18] J. Yang, J. Tiong, M. Kennard, W.A. Jefferies, Deletion of the GPI pre-
anchor sequence in human p97—A general approach for generating the
soluble form of GPI-linked proteins, Protein Expr. Purif. 34 (2004)
28–48.
[19] D. Collen, H.R. Lijnen, Molecular basis of fibrinolysis, as relevant for
thrombolytic therapy, Thromb. Haemost. 74 (1995) 167–171.
[20] U.K. Laemmli, Cleavage of structural proteins during the assembly of the
head of bacteriophage T4, Nature 227 (1970) 680–685.
[21] M.F. Gebbink, E.E. Voest, A. Reijerkerk, Do antiangiogenic protein
fragments have amyloid properties? Blood 104 (2004) 1601–1605.
1030 Y. Bertrand et al. / Biochimica et Biophysica Acta 1763 (2006) 1024–1030[22] D. Gingras, D. Labelle, C. Nyalendo, D. Boivin, M. Demeule, C.
Barthomeuf, R. Beliveau, The antiangiogenic agent Neovastat (AE-941)
stimulates tissue plasminogen activator activity, Invest New Drugs 22
(2004) 17–26.
[23] J.E. Portielje, W.H. Kruit, A.J. Eerenberg, M. Schuler, A. Sparreboom,
C.H. Lamers, R.L. Bolhuis, G. Stoter, C. Huber, C. Hack, Interleukin 12
induces activation of fibrinolysis and coagulation in humans, Br.
J. Haematol. 112 (2001) 499–505.
[24] A. Reijerkerk, E.E. Voest, M.F. Gebbink, No grip, no growth: the
conceptual basis of excessive proteolysis in the treatment of cancer, Eur.
J. Cancer 36 (2000) 1695–1705.
[25] M.L. Kennard, H. Feldman, T. Yamada, W.A. Jefferies, Serum levels of the
iron binding protein p97 are elevated in Alzheimer's disease, Nat. Med. 2
(1996) 1230–1235.
[26] L. Medved, G. Tsurupa, S. Yakovlev, Conformational changes upon
conversion of fibrinogen into fibrin. The mechanisms of exposure of
cryptic sites, Ann. N. Y. Acad. Sci. 936 (2001) 185–204.
[27] L. Lorand, Factor XIII: structure, activation, and interactions with
fibrinogen and fibrin, Ann. N. Y. Acad. Sci. 936 (2001) 291–311.
[28] J.S. Palumbo, J.M. Potter, L.S. Kaplan, K. Talmage, D.G. Jackson, J.L.
Degen, Spontaneous hematogenous and lymphatic metastasis, but notprimary tumor growth or angiogenesis, is diminished in fibrinogen-
deficient mice, Cancer Res. 62 (2002) 6966–6972.
[29] J.P. Collet, G. Montalescot, C. Lesty, Z. Mishal, J. Soria, R. Choussat, G.
Drobinski, C. Soria, P. Pinton, P. Barragan, D. Thomas, Effects of
Abciximab on the architecture of platelet-rich clots in patients with acute
myocardial infarction undergoing primary coronary intervention, Circula-
tion 103 (2001) 2328–2331.
[30] C.W. Francis, D.H. Kraus, V.J. Marder, Structural and chromatographic
heterogeneity of normal plasma fibrinogen associated with the presence of
three gamma-chain types with distinct molecular weights, BBA (1983)
155–164.
[31] R.Marchi, S.S.Mirshahi, C. Soria,M.Mirshahi,M. Zohar, J.P. Collet, N.B.
de Bosch, C.L. Arocha-Pinango, J. Soria, Thrombotic dysfibrinogenemia.
Fibrinogen “Caracas V” relation between very tight fibrin network and
defective clot degradability, Thromb. Res. 99 (2000) 187–193.
[32] A. Blinc, J. Magdic, J. Fric, I. Musevic, Atomic force microscopy of fibrin
networks and plasma clots during fibrinolysis, Fibrinolysis Proteolysis 14
(2000) 288–299.
[33] A. Sahni, C.W. Francis, Stimulation of endothelial cell proliferation by
FGF-2 in the presence of fibrinogen requires alphavbeta3, Blood 104
(2004) 3635–3641.
